<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334890</url>
  </required_header>
  <id_info>
    <org_study_id>SEPTMON</org_study_id>
    <nct_id>NCT03334890</nct_id>
  </id_info>
  <brief_title>CRC Post-surgical Assessment and Recurrence Monitoring</brief_title>
  <official_title>Colorectal Cancer Post-surgical Therapeutic Effect Assessment and Recurrence Monitoring by Methylated SEPT9</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioChain (Beijing) Science and Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospitals affiliated to the China PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>309th Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioChain (Beijing) Science and Technology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The surgical therapeutic effect of stage II-IV CRC patients will be assessed by the plasma
      mSEPT9 assay, and patients will be followed up by the same assay for recurrence monitoring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of surgical therapeutic effect of colorectal cancer (CRC) relies on computer
      tomography (CT) and serum CEA test. CT cannot be used frequently to monitor the instant
      change of lesions, while CEA cannot cover all patients due to its low sensitivity. The
      objective of this study is to assess the performance of the methylated SEPT9 (mSEPT9) in
      assessing the surgical therapeutic effect of CRC.

      This study plans to recruit 50 CRC patients with stage II-IV CRC. Plasma samples before
      surgery, one day after surgery and seven days after surgery will be collected from each
      subject. mSEPT9 level will be measured at 3 months, 6 months, 9 months, 12 months, 18 months
      after surgery and relevant chemotherapy to monitor the possible recurrence of CRC. The mSEPT9
      level will be measured by the Epi proColon 2.0 assay. The serum CEA will be measured parallel
      at the identical time points.

      Primary outcomes include the plasma mSEPT9 levels before surgery, one and seven days after
      surgery.

      Secondary outcomes include the serum CEA levels before surgery, one and seven days after
      surgery. It also includes the size of cancer for each patients, the ratio of patients with
      mSEPT9 complete response (CR), partial response(PR), progressive disease (PD) and stable
      disease (SD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mSEPT9 level</measure>
    <time_frame>Jan 1, 2016 to Dec 31, 2017</time_frame>
    <description>the Ct values representing the mSEPT9 level in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CEA level</measure>
    <time_frame>Jan 1, 2016 to Dec 31, 2017</time_frame>
    <description>the serum CEA level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor size</measure>
    <time_frame>Jan 1, 2016 to Dec 31, 2017</time_frame>
    <description>the maximal diameter of tumor measured with CT images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR,PR,SD,PD</measure>
    <time_frame>Jan 1, 2016 to Dec 31, 2017</time_frame>
    <description>complete response, partial response, stable disease, progressive disease</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>plasma mSEPT9 level</intervention_name>
    <description>the plasma level of methylated SEPT9</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma samples from CRC patients before surgery, one day and seven days after surgery
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        stage II-IV CRC patients planning to performe surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage II-IV CRC patients planning to perform surgery

        Exclusion Criteria:

          -  stage 0-I CRC patients, patients with history of CRC or other cancers, patients not
             suitable for surgery, pregnant women, patients younger than 30 or older than 80.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lele Song, M.D.,Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Chinese PLA 309th Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lele Song, M.D.,Ph.D.</last_name>
    <phone>86-13240149188</phone>
    <email>songlele@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Chinese PLA 302th hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Chen</last_name>
    </contact>
    <investigator>
      <last_name>Yinying Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chinese PLA 309th hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lele Song, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Yuemin Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chinese PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaohua Guo, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hongyi Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of the Chinese PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiumei Peng, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Wenhua Xiao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>309th Hospital of Chinese People's Liberation Army</investigator_affiliation>
    <investigator_full_name>LELE SONG</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>septin 9</keyword>
  <keyword>SEPT9</keyword>
  <keyword>methylation</keyword>
  <keyword>CEA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

